Professional Documents
Culture Documents
Case Report: DR Aurore Blésius Institut Gustave Roussy
Case Report: DR Aurore Blésius Institut Gustave Roussy
Case Report: DR Aurore Blésius Institut Gustave Roussy
Case report
48 year old man. November 2006: left kidney mass for abdominal pain. Wide surgery by : radical nephrectomy with splenectomy and partial pancreatectomy. Clear cell carcinoma T4N0 grade 3 Resection was complete
Case report
March 2007: local relapse with 2 lung mets. PS status : 1. Intermediate risk group (MSKCC classification). April 2007: Sunitinib started at standard dose-> 50mg 4 weeks on/ 2 weeks off.
Case report
2 weeks after treatments start : emergency admission for fever , severe hypertension, headache and bradycardia. Biology: hyperkaliemia with renal failure The first assesment by contrast ultra-sound technic described decrease of local relapse with dramatic change in tumor vascularisation.
Baseline
Case report
Diagnosis: tumor lysis syndrom Sunitinib restarted 2 weeks later at 25mg continuous PR was observed until October 2009. Lung mets have disappeared 30 months of treatment = 30 months of PR !
Case report
October 2009: strong and rough anemia (7g/dl) and deterioration of general status. Intracolic mass was observed on coloscopy . CT-scan confirmed presence of abdominal mass developped from colon (suggestive of colon cancer for endoscopist).
Case report
Biopsy: metastasis of clear cell carcinoma. Andretrospectively, a tiny intra-colic lesion was present on the CT-scan in March 2009
Case report
Patient underwent wide resection of its abdominal tumor with resection of jejunum and left colon (11. 09) , with colostomy . Closing of colostomy in January 2010. Currently patient is still in CR , without restart of Sunitinib since October 2009 (last CT scan: April 2010).
Comments
Tumor lysis syndrom can be observed with anti-angiogenic drugs (Michels J et al., Invest
New Drugs .2009)
Acute anemia should prompt search for occute bleeding from digestive metastasis CR can be achieved with combination of medical and surgical therapy Whether antiangiogenic drugs should have been restarted remains questionable